SWM
ANIK icon

SHP Wealth Management’s Anika Therapeutics ANIK Stock Holding History

SHP Wealth Management’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.96K Hold
681
– – ﹤0.01% 986
2026
Q1 		$9.87K Hold
681
– – ﹤0.01% 896
2025
Q4 		$6.54K Buy
+681
New +$6.52K ﹤0.01% 929

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CM
Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
IP
Indivisible Partners Clearwater, Florida $1.77B AUM
CWP
Curated Wealth Partners El Segundo, California $774M AUM 5.71% 1-Year Est. Return

SHP Wealth Management's ANIK Position: Q2 2026 in Review

SHP Wealth Management held its Anika Therapeutics (ANIK) position steady in Q2 2026 at 681 shares worth $9.96K. The position accounts for ﹤0.01% of the portfolio, ranked #986.

SHP Wealth Management first reported a position in ANIK in Q4 2025 and has held it in 3 quarters since. 48 funds tracked by Wall St. Rank hold ANIK as of Q2 2026.

  • SHP Wealth Management held 681 shares of Anika Therapeutics worth $9.96K as of Q2 2026.
  • SHP Wealth Management left its Anika Therapeutics share count unchanged in Q2 2026.
  • Anika Therapeutics made up ﹤0.01% of SHP Wealth Management's portfolio in Q2 2026, its #986 holding.
  • SHP Wealth Management first reported a position in Anika Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 48 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2026.

Based on SHP Wealth Management's 13F filing for Q2 2026, filed 11 Aug 2026.